7Development Reports Clause Samples
7Development Reports. No less frequently than [***], VERASTEM shall provide CHUGAI with written reports summarizing its, its Affiliates’, and its sublicensees’ development of Product, including a summary of the data, timelines and results of such development, and an overview of future development activities reasonably contemplated by VERASTEM, which reports shall be provided in English. Such reports shall be the Confidential Information of VERASTEM pursuant to Article 10. VERASTEM shall respond to CHUGAI’s reasonable requests for additional information regarding significant development activities, as CHUGAI may request from time to time.
7Development Reports. (a) Marinus shall provide Licensee with written reports, at each regular JSC meeting, summarizing its, its Affiliates’ and its sublicensees’ activities with respect to the Development of Licensed Products for use in the Field in the Territory. Such reports and all data therein shall constitute Confidential Information of Marinus pursuant to Article 9.
(b) Licensee shall provide Marinus with written reports, at each regular JSC meeting, summarizing its, its Affiliates’ and its sublicensees’ activities with respect to Development of Licensed Products for use in the Field in the Territory. Such reports and all data therein shall constitute Confidential Information of Licensee pursuant to Article 9.
7Development Reports. From and after the Effective Date, each Party shall provide to the other Party, within [***] following the end of each Calendar Quarter: (a) a detailed written report of the applicable Development activities conducted during such Calendar Quarter, which report shall contain sufficient detail to enable the JDC to assess each Party’s compliance with the Development Plan and this Agreement; and (b) access to or copies of any written reports related to such Development activities (or results and analyses thereof) as may be prepared by or on behalf of such Party or its Affiliates.
7Development Reports. (a) For Development activities with respect to Licensed Products for which Protagonist has not exercised an Opt-Out Right, each Party will provide to the JDC: (i) no later than [***] after the same becomes available, any material information and data arising from the Development of Licensed Products by such Party, including the finalized top line memorandum for any and all Clinical Trials and nonclinical studies conducted for the Licensed Products, in each case under the applicable Joint Global Development Plan (and as soon as practicable after the same is available, each Party will provide ongoing access to the other Party to any tables, listings, figures and other data generated thereunder); and (ii) at least [***] in advance of each regularly scheduled meeting of the JDC, any other relevant information and data arising from the performance of Development activities by such Party for the Licensed Products under the applicable Joint Global Development Plan since the last such meeting to the extent not previously disclosed in connection with day-to-day interactions between the Parties. In addition, at the first JDC meeting in the following Calendar Year, each Party will provide an annual review for the Calendar Year-ended of results versus goals of Development activities for the Licensed Products under the applicable Joint Global Development Plan.
(b) No less than [***] per [***], Takeda will provide to Protagonist a written report summarizing (i) Takeda’s material Development activities for the Licensed Products for the Ex-U.S. Territory and, as applicable, the Opt-Out Products for the U.S., during the prior [***] period, (ii) Takeda’s plans for material Development for the Licensed Products for the Ex-U.S. Territory and, as applicable, the Opt-Out Products for the U.S., in the upcoming [***] period, and (iii) any material changes in Takeda’s regulatory strategy for the Licensed Products for the Ex-U.S. Territory and, as applicable, the Opt-Out Products for the U.S., since the last report.
